Innovation Drives Divergence: US FDA Drugs and Biologics Centers Follow Own Trajectories

Regenerative medicines using expedited review pathways dominate novel approvals at the Center for Biologics Evaluation and Research, while the Center for Drug Evaluation’s higher volume comes with lower first-cycle approval rates and more standard reviews.